CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma

By sjmartinez • July 11, 2024

Pophali PA, Fein JA, Ahn KW, Allbee-Johnson M, Ahmed N, Awan FT, Farhan S, Grover NS, Hilal T, Iqbal M, Maakaron J, Modi D, Nasrollahi E, Schachter L, Sauter CS, Hamadani M, Herrera AF, Shouval R, Shadman M. CD19-directed CART Therapy for T cell/Histiocyte Rich Large B-cell Lymphoma. Blood Adv. 2024 Jul 10:bloodadvances.2024013863. doi: 10.1182/bloodadvances.2024013863. Epub ahead of print. PMID: 38985302.

Tags: Hematology/Oncology, Publications

Blocking Deoxycytidine Kinase in Activated Lymphocytes Depletes Deoxycytidine Triphosphate Pools and Alters Cell Cycle Kinetics to Yield Less Disease in a Mouse Multiple Sclerosis Model

Salas JR, Ryan KM, Trias AO, Chen BY, Guemes M, Galic Z, Schultz KA, Clark PM. Blocking Deoxycytidine Kinase in Activated Lymphocytes Depletes Deoxycytidine Triphosphate[...]

Targeting ketone body metabolism in mitigating gemcitabine resistance

Rohena-Rivera K, You S, Kim M, Billet S, Ten Hoeve J, Gonzales G, Huang C, Heard A, Chan KS, Bhowmick NA. Targeting ketone body metabolism[...]

Olutasidenib demonstrates significant clinical activity in mutated IDH1 acute myeloid leukaemia arising from a prior myeloproliferative neoplasm

De Botton S, Récher C, Cortes J, Curti A, Fenaux P, Peterlin P, Pigneux A, Yee K, Wei A, Mims A, Schiller G, Chao MM,[...]